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Background: Nocebo effects contribute to a large proportion of the non-specific
side-effects attributed to medications and are mainly generated through negative
expectations. Previous reviews show that interventions designed to change participants’
expectations have a small effect on pain experience. They are also effective in reducing
side-effects caused by exposure to sham medications. To date, there has been no
review of the influence of such interventions on symptoms attributed to real medicinal
treatments.
Objective: To review studies using a randomized controlled design testing the effect
of brief psychological interventions compared to usual practice on the side-effect
experience to medicinal treatments in healthy volunteers and patients.
Methods: We searched Web of Science, Scopus, Medline, PsycINFO, PsycARTICLES,
and Cochrane CENTRAL using search terms for randomized controlled trials along with
“nocebo,” “placebo effect,” “medication,” “side-effects,” and associated terms. Studies
were eligible if they studied a human population, used an active medicine, delivered a
brief psychological intervention intended to influence side-effect reporting compared to
usual care or no intervention, and used a randomized controlled design. Because of
the heterogeneity of the literature we used a narrative synthesis and assessed evidence
quality using the GRADE approach.
Results: Our database search and supplementary search of the reference sections of
included studies retrieved 50,140 citations. After screening, full text review and manual
reference searches, 27 studies were included. The quality of the studies and evidence
was judged to be low. The strongest and most consistent effect came from omitting
side-effect information, although surprisingly de-emphasizing side-effects did not affect
side-effect reporting. Other techniques, including priming, distraction, and altering the
perception of branding, produced mixed results.
Conclusion: Brief psychological interventions can influence side-effect reporting to
active medications. Research is currently investigating new ways to de-emphasize
side-effects whilst still upholding informed consent, but larger confirmatory trials with
suitable control groups are needed. The literature in this area would be improved by
more detailed reporting of studies.
Keywords: review, side-effects, medicine, nocebo effect, interventions, side-effect information
Webster and Rubin Influencing Side-Effects Through Psychological Interventions
INTRODUCTION
Nocebo effects, sometimes dubbed the placebo effect’s “evil
twin,” are the experience of noxious symptoms in response
to an inert exposure (1). Nocebo effects can also refer to
negative clinical outcomes which are not attributable to the actual
pharmacological or physiotherapeutic action of an intervention
(2). It is estimated that between 38 and 100% of side-effects
reported to drugs taken for a large range of medical conditions
are related to the treatment context, rather than the active
ingredients of the medication itself (3).
These nocebo-related side-effects are important, as they can
affect a patient’s well-being (4) and influence their decision as
to whether to adhere to their treatment regimen (5, 6). For
example adverse media coverage surrounding the safety of statins
and their reported side-effects has resulted in around 2,00,000
patients who are no longer taking their statins as directed leading
to a predicted increase of 2,000 cardiovascular events in the next
decade (7). This is despite the fact that most of these side-effects
are probably nocebo-related (8). Perhaps unsurprisingly, side-
effects can also result in substantial additional health care costs
in terms of additional primary care and hospital visits and also
the cost of wasted medication due to non-adherence (9).
Of the multiple factors that may contribute to the
development of nocebo effects, expectations of symptoms
appear to be the main contributor. These can be generated
through verbal and written suggestions about what symptoms
to expect, be implied by the apparent dose of a drug, and be
learnt through classical conditioning and social observation
(10). Studies have used these psychological mechanisms as a
means to alter peoples’ experience of experimentally induced
pain (11), as well as pain following acute medical procedures,
such as injections (12) and surgery (13). These effects have been
studied in multiple reviews, showing that brief psychological
interventions designed to change expectation of pain following
treatment have a small but reliable effect on relieving patients’
pain compared to usual care (14–16).
However, to our knowledge, there has been no review of
whether such interventions can alter patient experience ofside-
effects to medicinal treatments. Although evidence demonstrates
that such interventions can be effective in altering side-effects
reported following exposure to inert substances (10), it is
also important to assess if these effects can be transferred
to clinical practice. We therefore set out to review studies
using a randomized controlled design testing the effect of
brief psychological interventions compared to usual practice on
the side-effect experience to medicinal treatments in healthy
volunteers and patients. To answer the question: can brief
psychological interventions influence the side-effect experience
to medications?
METHODS
Our reporting of this systematic review adheres to the standards
for the Preferred Reporting Items for Systematic reviews
and Meta-Analyses (17). The protocol for this review was
prospectively registered on PROSPERO (CRD42018091903).
Identification of Studies
We searched the following electronic databases with a predefined
search strategy: Web of Science, Scopus, OvidSp (Medline,
PsycINFO, and PsycARTICLES) and Cochrane CENTRAL. We
included Web of Science and Scopus for their coverage of the
sciences and social sciences. OvidSp was chosen for its coverage
of journals chiefly in the area of health sciences, and also for
its inclusion of the databases PsycINFO and PsycARTICLES.
Cochrane CENTRAL was included due to its coverage of
randomized controlled trials and because it includes records
which are derived from other sources to the ones already chosen.
In preliminary work we tested a variety of search strategies
in an effort to balance specificity and sensitivity. Our final
search strategy used the recommended search terms to identify
randomized controlled trials (18) along with the terms and
associated words for “nocebo,” “placebo effect,” “medication,” and
“side-effects.” We used separate search strategies for each of
the databases as these needed to be modified due to differences
in MeSH terms, boolean operators and wildcards. A copy
the search strategy we used for Medline can be seen in the
Supplementary Material.
Review Process
The search was initially carried out on 22nd March 2018 and
updated on 22nd June 2018 following the identification of a
relevant study published between this time. The initial electronic
searches were combined using EndNote and duplicates were
identified and deleted. The titles and abstracts of citations were
then screened for potential relevance. If relevance was not clear
from the abstract, the study was taken forward to the full text
review. All full text versions of papers that were potentially
relevant were then screened in relation to the inclusion criteria.
Papers that met the inclusion criteria had their reference sections
manually searched for other studies that could be included.
Selection Criteria
Studies were eligible for inclusion in this review if they met the
criteria below.
Population
Human population (healthy volunteers, patients and children
were allowed).
Exposure
Active medicinal treatment (i.e., contains a pharmacological
agent), associated with side-effects.
Intervention
A brief, psychological intervention delivered in one session
and that could be feasibly introduced within a single doctor-
patient consultation or treatment appointment. By psychological
we mean an intervention that targets certain psychological
processes, such as cognitive expectations, attention or learning.
Interventions requiring biological or chemical stimuli were
excluded because these are not purely psychological. As we
wanted to identify interventions that could be easily incorporated
into clinical practice, in-depth psychological interventions, such
as cognitive behavior therapy, mindfulness, relaxation training
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or guided imagery, or that consisted of intensive educational
packages were excluded as these typically are not delivered in one
session and often take place over the course of a treatment.
Comparator
Usual care. We excluded studies with control conditions
involving a different type of intervention.
Outcome
We included studies with an outcome of side-effectsmeasured via
self-report or inferred through objective measures. We followed
the NICE (19) definition of a side-effect as “An effect of a drug
(or treatment or intervention) that is additional to the main
intended effect. It could be good, bad or neutral, depending
on the circumstances.” For some studies, e.g., those concerning
infant experience to vaccinations, side-effects were measured
within minutes of the procedure. We excluded these on the bases
that the “side-effects” were presumably related to the insertion of
the needle rather than the effects of the vaccine itself.
Study Design
Used an experimental design in which participants were
randomized or quasi randomized to receive the intervention or
the control condition.
Other Criteria
Published in the English language.
Data Extraction
We extracted data from the final set of studies using a data
extraction table developed for this systematic review. Data
extracted included the study design and methodology, main
demographics of participants, description of intervention and
control conditions, side-effect measures, statistical approach
and results. We also extracted details about the mode of the
intervention, its content and duration.
Quality Assessment
We assessed the quality of all eligible studies using the Cochrane
Collaboration’s Risk of Bias tool for randomized controlled
trials (20).
Data Synthesis and Analysis
Due to the heterogeneity in the interventions that we included
and the way that side-effects weremeasured, scored and analyzed,
we used a narrative synthesis to analyse the results. There is
no general consensus on the best way to carry out a narrative
synthesis for systematic reviews (21). As such we decided to
use a weight of evidence approach by identifying the quality
of evidence for each type of intervention reviewed. To do this
we used the GRADE approach (22) which is a transparent
framework used to grade the quality of evidence included in
systematic reviews and the strength of recommendations.
RESULTS
Search Results
The database search retrieved 50,133 citations and searching the
reference lists of included studies retrieved another 7, giving
a total of 50,140. After removing duplicates 40,346 citations
remained. After screening titles and abstracts, we reviewed the
full text of 63 articles relating to 66 studies. Of these, 39 studies
were excluded for not meeting the inclusion criteria, resulting
in a total of 26 articles reporting on 27 studies. One article (23)
reported results on two separate studies and is referred to in the
text and tables as Study 1 or Study 2 where necessary. The number
of studies at each stage of the search strategy and the reasons for
exclusion are shown in Figure 1.
Study Characteristics
See Table 1 for a full summary of the characteristics of the
included studies. The 27 studies included in the review reported
on a total of 3,459 participants. There was a range of patient
groups and treatments under investigation. The most common
of these were patients with cancer receiving chemotherapy (26,
31, 39, 41–44, 46), and patients with depression prescribed
anti-depressants (29, 32, 35–37). All studies used a between
participants RCT design apart from Cildag et al. (24), Myers
and Calvert (36), Redd et al. (39), and Schagen et al. (42) which
used a quasi-randomized approach, and Faasse et al. (28) who
used a within-subjects RCT design. Some studies used a factorial
design in their RCT involving different experimental conditions
or baseline variables entered as independent factors (23, 31, 39,
41–43). In these cases, we have reported the main effects of the
relevant intervention under investigation.
There were a variety of interventions used by included studies.
We looked for common themes and content of the various
interventions andwere able to group the studies into five different
types, these were: priming, distraction, branding, omitting side-
effects, and de-emphasizing side-effects, plus a miscellaneous
group.
The majority of studies used an un-validated questionnaire
specifically designed for their study to measure side-effects, and
measures were generally completed within days/weeks following
treatment initiation.
Quality Assessment
The quality of included studies was poor (see Figures 2, 3).
The main problem was a lack of clear reporting within the
papers. Over half of the studies neglected to mention how they
carried out randomization, and four were at high risk for using a
quasi-randomized approach. Because of the unclear reporting of
random sequence generation, the risk for allocation concealment
bias followed a similar pattern, and six studies were at high risk
because their randomization approach allowed research staff to
foresee subsequent allocations. For blinding of participants and
personnel, studies often failed to state whether the experimenters
were blind to the manipulation that accompanied the active
treatment, leaving the risk of bias unclear. Only seven studies
used adequate blinding procedures, with one not using blinding
at all. Nineteen studies used side-effect measures which were
completed by participants, as such blinding of the outcome
assessment was judged unlikely to influence these results. For
the remaining eight studies it was unclear if participants filled
in the measures themselves or if they were administered by a
blind/non-blind member of the study team. For 16 studies, drop
outs were not addressed, or if they were, the paper typically failed
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FIGURE 1 | Flow diagram of the selection process of studies including the number of events and reasons for exclusion.
to explain how this affected the results, leaving the risk of bias
unclear; the remaining 11 studies provided adequate information
and reasoning behind drop outs. Only two studies had lodged
a protocol in a publicly accessible registry before the start of
recruitment, leaving us unable to assess the risk for selective
reporting for the remaining studies, apart from one in which
there was a change in the prespecified primary analysis suggesting
there was a high risk of bias.
Quality of the Evidence
The quality of evidence regarding priming, distraction, omitting
side-effect information and de-emphasizing side effects, and
doctor characteristic intervention(s) was very low. This is because
most of the information came from studies at low or unclear
risk of bias, in which plausible bias could alter the results. There
was also some evidence of inconsistency and imprecision in
the results due to opposite findings, wide confidence intervals
and some small studies which may not have been adequately
powered. Due to the broad nature of this systematic review, there
is no evidence of indirectness, as all included studies helped to
answer the question. It is plausible however, there may have
been some publication bias due to the preponderance of smaller
studies.
The quality of evidence regarding the branding intervention
studies was low. This was graded similarly due to the reasons
discussed for the above interventions, however the inconsistency
in the results could perhaps be explained by differences in the
interventions, and we judged that the small studies were probably
due to this literature representing an early evidence base, rather
than publication bias.
Finally, the quality of evidence for the deception intervention
was moderate. There was some imprecision evident and the
sample size was small, however the study was judged to have a low
overall risk of bias, and there was no evidence of indirectness. As
only one study was included, inconsistency and publication bias
could not be determined.
Effect of Interventions on Side-Effect
Reporting
Priming
Four studies looked at the effect of priming on side-effect
reporting following chemotherapy with mixed results (see
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TABLE 1 | Summary table of included studies.
References
(intervention
type)
Design Sample (N, M age,
%Male)
Treatment Experimental group (n) Control group (n) Side-effect
measure (main
outcome)
Timing of
measure
Cildag et al.
(24)
(Distraction)
Quasi RCT Patients undergoing
drug provocation test
(112, 41.8, 32.1)
Various drug
provocation
tests
Kept busy filling questionnaires, arranging
files and doing archiving (63)
Did not perform any tasks (49) ?
(yes)
During
provocation test
Cocco (25)
(Omitting)
RCT Patients with arterial
hypertension
(114, 57.7, 100)
Metroprolol 1. Metroprolol given under a code number
with no information about active
substance. Informed of all possible
side-effects apart from erectile
dysfunction (38)
2. Informed taking metroprolol and about
all possible side-effects apart from erectile
dysfunction (38)
Informed taking metroprolol and erectile
dysfunction might occur (38)
IIEF
(yes)
At the end of the
60-day trial
Colagiuri et al.
(26) (Priming)
RCT Patients undergoing
chemotherapy
(91, 60.5, 42.9)
Chemotherapy Assessed expectancies for nausea,
fatigue, sadness, and loss of appetite
before first infusion (46)
No assessment of expectancies (45) SSQ and EORTC
QLQ-C30
(yes)
After first
chemotherapy
cycle
Colgan et al.
(27)
(Branding)
RCT People with frequent
headaches
(69, 21, 21.7)
Branded and
generic
ibuprofen
Video interviewing health specialists and
providing accurate information addressing
misperceptions of generic medicines (34)
Video interviewing a neurologist about the
different types of headaches and their
global epidemiology (35)
Modified GASE
(no)
An hour after
taking ibuprofen
for a headache
Faasse et al.
(28)
(Branding)
RCCT Students with frequent
headache
(81, 20.8, 17)
Ibuprofen Ibuprofen labeled with the brand name
“nurofen” (81)
Ibuprofen labeled “generic ibuprofen” (81) SSQ
(yes)
An hour after
taking ibuprofen
for a headache
Faria et al.
(29)
(Misc)
RCT Patients with seasonal
affective disorder
(46, 31.8, 60.9)
Escitalopram Deceptively told they would receive the
active placebo, likely to induce side-effects
similar to escitalopram but out of which no
symptom-improvement could be expected
(22)
Correctly informed about the SSRI
treatment and the expected improvement
(24)
?
(no)
?
Flam et al.
(30)
(Omitting)
RCT Patients undergoing a
myelogram
(30, ?,43.3)
Myelogram 1. No tape-recorded message (10)
2. Tape-recorded message about the
techniques performed during a myelogram
(10)
Tape-recorded message about the
sensations to expect during a myelogram
(10)
Interview
(no)
The day following
the myelogram
Jacobs et al.
(31)
(Priming)
RCT Patients with breast
cancer
(175, 49.4, 0)
Chemotherapy 1. Informed about the possibility of
cognitive problems after chemotherapy
(56)
2. Same information plus reassurance that
there are still patients who score well on
memory tests (59)
Received a one sentence neutral
introduction without reference to
chemotherapy or cognitive difficulties (60)
Cognitive failure
questionnaire (yes)
After study
introduction
John et al.
(32)
(Omitting)
RCT Patients with
depression
(39, 34.0, 38)
Antidepressants Asked about their symptoms, their
prescription was explained to them and
they were encouraged to take their
medicines as advised (22)
Face-to-face, 10-min education session
about depression, treatment, efficacy and
adverse effects of the prescribed drug,
and plan of management (17)
KAE questionnaire
(no)
Six weeks after
prescription
Lauder et al.
(33)
(De-emphasizing)
RCT Patients undergoing
hysterectomy
(195, 43.4, 0)
Anesthesia Informed of the use of two perioperative
antiemetics to reduce the incidence of
emetic symptoms to anesthesia after
operation (95)
Informed that this was a study of
post-operative well-being with no
information about emetic symptoms (100)
Recorded by
nursing staff
(yes)
Immediately, 4, 8,
and 24 h after
surgery
(combined)
(Continued)
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TABLE 1 | Continued
References
(intervention
type)
Design Sample (N, M age,
%Male)
Treatment Experimental group (n) Control group (n) Side-effect
measure (main
outcome)
Timing of
measure
Mondaini
et al. (34)
(Omitting)
RCT Patients with benign
prostatic hyperplasia
(107, 60.5, 100)
Finasteride Finasteride concealed as an “X compound
of proven efficacy for the treatment of
BPH” (52)
Finasteride concealed as an “X compound
of proven efficacy for the treatment of
BPH. It may cause erectile dysfunction,
decrease libido, problems of ejaculation
but it is uncommon” (55)
Male sexual
function-4, and
SSQ
(yes)
12 months after
prescription
Mukherjee
and Sahay
(23)
Study 1
(Omitting)
RCT 2 × 2 Business graduates
(117, ?, ?)
Skin cream No information given. Price was
manipulated at two levels:
1. low (?)
2. high (?)
Read a news item about skin creams and
their potential side-effects. Price was
manipulated at two levels:
1. low (?)
2. high (?)
SSQ (yes) ?
Mukherjee
and Sahay
(23)
Study 2
(Omitting)
RCT 2 × 3 Business students
(149, ?, ?)
Skin Cream Presented with an excerpt devoid of any
negative aspects. Price was manipulated
at three levels
1. low (?)
2. high (?)
3. discounted (?)
Read a news item about skin creams and
their potential side-effects. Price was
manipulated at three levels
1. low (?)
2. high (?)
3. discounted (?)
SSQ
(yes)
?
Myers and
Calvert (35)
(Omitting)
RCT Patients with
depression
(93, 40.4, 39.8)
Amitriptyline Told only that the drug was being given to
cure their depression (46)
Told the drug was being given to cure their
depression and listed a series of
side-effect they might experience (47)
SSQ
(yes)
Two weeks after
initial dose
Myers and
Calvert (36)
(Omitting)
RCT Patients with
depression
(89, 38.9, 33.7)
Dothiepin Told only that the drug was being given to
cure their depression (43)
Told the drug was being given to cure their
depression and listed a series of
side-effect they might experience (46)
SSQ
(yes)
Two weeks after
initial dose
Myers and
Calvert (37)
(Omitting)
RCT Patients with
depression
(120, 43.3, 25.8)
Dothiepin 1. Told only that the drug was being given
to treat their depression and received no
written information (40)
2. Verbal and written information about
beneficial effects (40)
Verbal and written information about
side-effects (40)
SSQ
(no)
3 and 6 weeks
after prescription
O’Connor
et al. (38)
(De-emphasizing)
RCT Patients eligible for flu
vaccine (292, 52.5, 6.7)
Influenza
vaccine
Described the percentage who remain
influenza and side-effect free.
Accompanied by flip charts and decision
aid poster highlighting the key points (148)
Described the percentage who acquire
influenza and vaccine side effects.
Accompanied by flip charts and decision
aid poster highlighting the key points (144)
SSQ
(no)
3 days after
vaccination
Redd et al.
(39)
(Distraction)
Quasi RCT Pediatric patients
undergoing
chemotherapy
(26, 14.0, 73.2)
Chemotherapy Played from a choice of video games for
10min (13)
Permitted access to toys, books, games,
and television (13)
Visual analog scale
(yes)
10min later
Rickels et al.
(40)
(Misc)
RCT Patients with
psychiatric disorders
(169, 31.9, 34.3)
Tranquilisers Study doctor who was a psychiatrist that
was drug “enthusastic” (?)
Study doctor who was a psychiatrist that
was drug “skeptical” (?)
Recorded by
doctor
(no)
2 and 4 weeks
after prescription
(combined)
Roscoe et al.
(41)
(De-emphasizing)
RCT Patients with breast
cancer
(53, 51.5, 0)
Chemotherapy Handout showing positive interpretation of
the data from two acupressure band
studies. A 12min CD involving visualizing
pleasant scenes and explaining the
efficacy of the acupressure bands (25)
Handout thanked patients for participating
in the study, and the CD did not discuss
the efficacy of the bands (28)
Diary
(yes)
Each day for 5
days following
chemotherapy
(combined)
(Continued)
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TABLE 1 | Continued
References
(intervention
type)
Design Sample (N, M age,
%Male)
Treatment Experimental group (n) Control group (n) Side-effect
measure (main
outcome)
Timing of
measure
Schagen
et al. (42)
(Priming)
Quasi RCT
2 × 2 × 2
Patients with breast
cancer
(261, 53.7, 0)
Chemotherapy Told that some patients treated with
cytotoxic agents experience cognitive
problems and the goal of the study was to
obtain more insight into the relation
between chemotherapy and cognitive
problems’ (130)
Received a neutral introduction (131) SSQ
(yes)
After study
introduction
Schagen
et al. (43)
(Priming)
RCT
2 × 2
Patients with cancer
(236, 48.4, 10.1)
Chemotherapy Received the introduction that some
patients treated with chemotherapy
experience cognitive problems (116)
Received a neutral introduction (120) Cognitive failure
questionnaire
(yes)
After study
introduction
Shelke et al.
(44)
(De-emphasizing)
RCT Patients undergoing
chemotherapy
(322, 57.6, 27)
Chemotherapy Standard educational materials plus a
handout explaining how effective
ondansetron, would likely be in controlling
nausea and vomiting (159)
Standard educational materials given to
new patients (163)
SSQ
(no)
Treatment day until
four days after
(combined)
Silvestri et al.
(45)
(Omitting)
RCT Patients with newly
diagnosed CVD
(96, 52.0, 100)
Atenolol 1. Blinded to drug given (32)
2. Informed on drug given but not on the
side-effects (32)
Informed on drug given and its side-effects
on erectile function (32)
IIEF
(yes)
After 3 months of
treatment
Vasterling
et al. (46)
(Distraction)
RCT Patients with cancer
(60, 51, 35)
Chemotherapy Played video games during chemotherapy
treatment and told this would keep their
minds off their treatment, making it less
unpleasant and reducing the severity of its
side effects (?)
Rested quietly in the treatment room
before chemotherapy and told if a patient
was relaxed, it would be less unpleasant,
and the severity of the side-effects would
be reduced (?)
SSQ
(no)
After each of the 5
chemotherapy
sessions
(combined)
Wilhelm et al.
(47)
(De-emphasizing)
RCT Healthy males
(80, 24.5, 100)
Metoprolol Informed of side-effects including
headache, stomach pain or nausea.
Dizziness is also mentioned, but is
explained as a sign that the drug is
starting to work and means that your body
is responding to the beta-blocker
particularly well (40)
Informed of side-effects including
headache, stomach pain or nausea.
Dizziness is also mentioned and explained
as a potentially unpleasant, but already
known side-effect of the drug (40)
Modified GASE
(yes)
?
Wise et al.
(48)
(Omitting)
RCT Patients with Asthma
(237, 37, 23.8)
Montelukast The computer presentation showed the
same basic education but did not show
positive messages about the expected
benefits of montelukast and did not
contain the television commercial. The
capsules were off-white and referred to as
montelukast (117)
Viewed a computer presentation for
10–20min emphasizing the value and
potency of the treatment including a
television commercial for montelukast. The
commercial also described potential
side-effects. The capsules were 2-tone
blue, and referred to as Singulair (120)
?
(no)
After 2 and 4
weeks of
treatment
(combined)
RCT, randomized controlled trial; RCCT, randomized controlled crossover trial; ?, not reported; CVD, cardiovascular disease; IIEF, international index of erectile dysfunction; SSQ, study specific questionnaire; EORTC QLQ-30, European
Organization for Research and Treatment of Cancer Quality of Life Questionnaire; GASE, generic assessment of side effects scale; KAE, knowledge, attitudes, and experiences questionnaire.
F
ro
n
tie
rs
in
P
syc
h
ia
try
|
w
w
w
.fro
n
tie
rsin
.o
rg
7
F
e
b
ru
a
ry
2
0
1
9
|V
o
lu
m
e
9
|
A
rtic
le
7
7
5
Webster and Rubin Influencing Side-Effects Through Psychological Interventions
FIGURE 2 | Quality assessment across included studies.
FIGURE 3 | Quality assessment between included studies.
Table 2). Colagiuri et al. (26) found a slight trend for priming
patients by assessing their expectancies for side-effects vs.
no assessment on subsequent nausea. Jacobs et al. (31) and
Schagen et al. (42) found no indication of an effect of priming
patients by mentioning that chemotherapy is associated with
cognitive problems on retrospectively reported cognitive side-
effects. However, Schagen et al. (43) in a similar study did find a
small effect of priming leading to increased reporting of previous
cognitive side-effects to chemotherapy compared to those in a
control group who received no such information.
Distraction
Three studies looked at the effect of distraction on side-effect
reporting following chemotherapy and drug provocation tests,
showing some evidence that distraction can reduce side-effect
reporting (see Table 3). Cildag et al. (24) found that keeping
patients busy with filling/archiving files significantly reduced the
occurrence of adverse reactions compared to a control group, but
only by a small amount. Redd et al. (39) found that distracting
pediatric cancer patients with video games significantly reduced
chemotherapy nausea from baseline, compared to those in the
control group. However, for adult cancer patients, Vasterling
et al. (46) found that video games were not effective in reducing
chemotherapy nausea or vomiting compared to a control group.
Branding
Two studies looked at the effect of branding on side-effect
reporting to ibuprofen showing some evidence that branding can
affect side-effect reporting (see Table 4). Colgan et al. (27) found
that a video designed to correct participants’ beliefs about generic
medicines significantly reduced side effects for both branded and
generic ibuprofen compared to those in a control group, showing
a large effect. However, Faasse et al. (28) found that simply
changing the labeling of ibuprofen from branded to generic did
not significantly affect side-effect reporting.
Omitting Side-Effect Information
Eleven studies looked at the effect of omitting side-effect
information on side-effect reporting to a range of different
treatments, showing that omitting side-effects significantly
decreases side-effect reporting (see Table 5). Eight studies
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TABLE 2 | Priming intervention results.
References Side-effect outcome and analysis Results Effect size (95% CI) Evidence quality
Colagiuri et al.
(26)
Occurrence: Multiple logistic regression Nausea: Ns, priming group > control group,
p = 0.06
OR = 3.19 (0.95, 10.69)
+ Very Low
Fatigue, sadness, loss of appetite: Ns, lowest
p = 0.31
–
Severity: Multiple linear regression Nausea, fatigue, sadness, loss of appetite: Ns,
lowest p = 0.24
–
Jacobs et al.
(31)
Frequency: 2 × 2 ANCOVA-group and
chemotherapy experience as independent
factors
Cognitive problems: Ns for those with
chemotherapy experience
–
Schagen
et al. (42)
Severity: 2 × 2 × 2 ANOVA-group, pre-existing
knowledge, and chemotherapy experience as
independent factors
Cognitive problems: Ns, priming group
(M = 2.53, SE = 0.11) < control group
(M = 2.68, SE = 0.12) for those with
chemotherapy experience, p = 0.34
d = −0.11 (−0.36, 0.13)
Other complaints: Ns, priming group (M = 3.00,
SE = 0.09) > control group (M = 2.95,
SE = 0.10) for those with chemotherapy
experience, p = 0.75
d = 0.05 (−0.20, 0.29)
Schagen
et al. (43)
Severity: 2 × 2 ANOVA-group and
chemotherapy experience as independent
factors
Cognitive problems: Priming group (M = 21.20,
SD = 6.4) > control group (M = 18.98,
SD = 6.7) for those with chemotherapy
experience, p = 0.032
d = 0.34 (0.08, 0.60)
Ns, non-significant; M, mean; SE, standard error; SD, standard deviation; OR, odds ratio; d, Cohen’s d; –, insufficient detail to calculate effect size.
TABLE 3 | Distraction intervention results.
References Side-effect outcome and analysis Results Effect size (95% CI) Evidence quality
Cildag et al. (24) Occurrence: Chi square Adverse reaction: Distraction group
(7.9%) < control group (34.7%), p = 0.0004
OR = 0.16 (0.05, 0.48)
+ Very Low
Redd et al. (39) Severity: Repeated measures ANOVA-group as
an independent factor and time as a
within-groups factor
Nausea: Distraction group (M
decrease = −16.92, SD = 8.70), p < 0.001.
Control group (M decrease = −1.77, SD = 8.96),
p > 0.05
–
Vasterling et al. (46) Frequency: Univariate analysis Vomiting: Ns –
Severity: Univariate analysis Nausea: Ns –
Ns, non-significant; M, mean; OR, odds ratio; –, insufficient detail to calculate effect size.
found that not informing patients about potential side-effects
significantly decreased side-effect reporting to metropolol (25),
a myelogram (30), antidepressants (32), finasteride (34), skin
cream (23) (study 1 and 2), atenolol (45), and montekulast
(48) compared to a control group which received side-effect
information, each showing large effect sizes. Similarly Myers
and Calvert (36) found a trend for a decrease in side-effect
reporting when patients were not informed about the side-
effects to the antidepressant dothiepin compared to a control
group, and Myers and Calvert (37) found that side-effects
significantly decreased to dothiepin when comparing the group
that only received beneficial information to groups that received
no information and side-effect information. Only one study,
Myers and Calvert (35), found no effect of side-effect information
on subsequent side-effect reporting.
De-emphasizing Side-Effects
Five studies looked at the effect of de-emphasisng side-effects on
side-effect reporting to range of different treatments, showing
evidence that this seems to have no effect (see Table 6). Three
studies found that informing patients of side-effects but in a way
that does not make them seem as bad had no effect on side-
effect reporting to anesthesia (33), or chemotherapy (41, 44),
however this was compared to a control group that did not
receive any information about side-effects. O’Connor et al. (38)
found that positively framing side-effects to emphasize those that
remain side-effect free and comparing to a control group that
received standard information about side-effects significantly
reduced side-effect reporting to the flu vaccine. Wilhelm et al.
(47) found that positively framing side-effects by explaining
they are a sign that the drug is working did not significantly
reduce side-effects tometoprolol compared to those who received
standard information.
Other Interventions
Two other studies investigated interventions which do not fall
into the above categories (seeTable 7). Faria et al. (29) deceptively
told seasonal affective disorder patients that they would receive
an active placebo which would produce similar side-effects to
escitalopram when in fact they received the active drug itself
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TABLE 4 | Branding intervention results.
References Side-effect outcome and analysis Results Effect size (95% CI) Evidence quality
Colgan et al. (27) Frequency: Linear mixed models Side-effects across both types of ibuprofen: Generic
medicines video group (M = 1.18, SE = 0.40) < control
group (M = 2.57, SE = 0.39), p = 0.02
d = −0.68 (−1.17, −0.20)
++ Low
Side-effects within each type of ibuprofen: Generic
medicines video group < control group, for both branded,
p = 0.02, and generic, p = 0.035
–
Faasse et al. (28) Severity: Linear mixed models Side-effects: Ns, branded (M = 3.41, SE = 0.47) >
generic (M = 2.95, SE = 0.46) ibuprofen, p = 0.16.
–
Ns, non-significant; M, mean; SE, standard error; d, Cohen’s d; –, insufficient detail to calculate effect size.
and found this showed a trend in decreasing reported side-
effects compared to a control group whowere correctly informed.
Rickels et al. (40) found no effect of the prescribing psychiatrist
being a drug “enthusiast” or drug “skeptical” on reported side-
effects to tranquilisers among psychiatric patients.
DISCUSSION
Summary of Main Findings
Although previous literature has looked at altering side-effects
generated in response to inert exposures, it is important to
test if these interventions also work in the clinical setting and
affect side-effects to real medications which may be initiated
or exacerbated through a nocebo effect. This can then provide
the basis for introducing into clinical practice strategies to
reduce these side-effects. Unfortunately, the quality of the studies
identified in this review were generally low quality mainly due
to the lack of clear reporting, inadequate randomization and
allocation procedures, and unpowered effects. Our overriding
recommendation, therefore, is that additional, better quality
work is needed in this field.
This point notwithstanding, from the results of the included
studies, the strongest and most consistent effect in altering
side-effects experienced following medical treatments was
omitting information about side-effects. Other techniques,
such as priming, distraction and altering the perceptions of
branding produced mixed results. More tentatively, studies
which investigated over the counter medications, common
prescription medications, and vaccines seemed to be more
susceptible to these interventions than those which studied
chemotherapy.
The finding that omitting side-effect information produced
the most consistent and strongest effect supports the evidence
from the literature on inert exposures (10) which recommends
that in order to reduce side-effects induced by nocebo effects
we should avoid giving suggestions of side-effects associated
with medications to patients. It also echoes what is found in
experimental nocebo studies which find that altering information
about side-effects alters side-effect experience to infrasound
(49), and electrical pain stimuli (50). In addition, this supports
previous work showing that interventions designed to change
patients’ expectations of pain by altering verbal suggestions
about the pain to expect after a treatment or procedure can
relieve (placebo) or increase (nocebo) patients baseline pain
depending on the suggestion (15, 16), highlighting the role
that expectations play in both placebo and nocebo effects.
Perhaps unsurprisingly no study looked at the effect of omitting
information about side-effects to chemotherapy, and therefore
we cannot say if the results extend to chemotherapy too.
However, as chemotherapy is already well-known for its side-
effects, it may be that omitting side-effect information would
do little to alter subsequent side-effect reporting in this
group.
Not mentioning side-effects to patients in order to reduce
these effects is ethically problematic and may not meet the
requirements of informed consent, something which has been
widely discussed in the literature (51, 52). An alternative
approach is to explain the potential side-effects to patients in
a way that de-emphasizes them and reduces their apparent
likelihood or severity (53). At first look, the results of studies
which have used this approach do not appear promising. Most
studies have showed no effect of de-emphasizing side-effects
on subsequent side-effect experience. However, this might be
an artifact relating to the design of these studies, in which the
groups that received the de-emphasized side-effect information
were compared to a control groups that received no side-effect
information at all. Explaining side-effects to patients, albeit in a
positive light, is still likely to increase the perceived likelihood of
side-effects compared to not describing side-effects. It would be
interesting for future studies to test the effects of de-emphasizing
side-effects of medication compared to a suitable control group
which receives standard side-effect information. In other studies
which used an appropriate control group, positive framing of
side-effects was shown to be beneficial, a finding that has also
been reproduced in healthy adults taking an inert tablet (54).
There is also scope for further investigations about framing the
side-effects of medication as a sign that the drug is working.
This was investigated in a pilot study that, although not powered
to find an effect, nonetheless showed a decrease in side-effect
measures among participants who believed the medicine to
be harmful (47). This idea of de-emphasizing side-effects has
shown some promise in the placebo literature on pain, in which
positive messages which focus more on the beneficial outcome
of treatments rather than the potential side-effects may be
more effective in relieving patients pain compared to usual care
messages (14).
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TABLE 5 | Omitting side-effect information intervention results.
References Side-effect outcome and
analysis
Results Effect size (95% CI) Evidence quality
Cocco (25) Occurrence: Chi square Erectile dysfunction: No side-effect information group (8%) < drug
information group (13%) < control group (32%), p < 0.01
–
+ Very Low
Flam et al. (30) Frequency: Independent t
test
Side-effects: Procedural information group (M = 2.1) < control
group (M = 4.3), p < 0.05
d = −0.94 (−1.86, −0.02)
Side-effects: No side-effect information group (M = 1.6) < control
group (M = 4.3), p < 0.05
d = −1.23 (−2.19, −0.27)
John et al. (32) Frequency: Mann Whitney U Side-effects: No side-effect information group (M = 1.7, SD = 1.9)
< control group (M = 3.5, SD = 2.6), p = 0.044
d = −0.81 (−1.47, −0.15)
Mondaini et al. (34) Occurrence: Mann Whitney
U
One or more side-effects: No side-effect information group (15.3%)
< control group (43.6%), p = 0.03
OR = 0.23 (0.09, 0.59)
Erectile dysfunction: No side-effect information group (9.6%) <
control group (30.9%), p = 0.02
OR = 0.24 (0.08, 0.70)
Decreased libido: No side-effect information group (7.7%) < control
group (23.6%), p = 0.04
OR = 0.27 (0.08, 0.89)
Ejaculation disorders: Ns, No side-effect information group (5.7%) <
control group (16.3%), p = 0.06
OR = 0.31 (0.08, 1.23)
Mukherjee and
Sahay (23) study 1
Severity: Two-way ANCOVA
with group and price as
independent factors
Skin dryness: No side-effect information group < control group,
p = 0.01
ηp2 = 0.05
Skin dryness: Ns difference between pricing, p > 0.70 –
Skin dryness: Interaction between pricing and side-effect
information, p = 0.02. No side-effect information group (M = 1.85,
SD = 1.38) < control group (M = 3.39, SD = 1.98) at low price. Ns
between no side-effect information group (M = 2.51, SD = 1.09)
and control group (M = 2.72, SD = 1.51) at high price
ηp2 = 0.04
Mukherjee and
Sahay (23) study 2
Severity: Two-way ANCOVA
with group and price as
independent factors
Skin dryness: No side-effect information group < control group,
p = 0.01
ηp2 = 0.04
Skin dryness: Ns difference between pricing, p = 0.32 –
Skin dryness: Ns interaction between pricing and side-effect
information, p = 0.19
–
Myers and Calvert
(35)
Occurrence: Chi square Side-effects: Ns, no side-effect information group (73.9%) < control
group (80.9%), p > 0.05
OR = 0.67 (0.25, 1.79)
Myers and Calvert
(36)
Occurrence: Chi square Side-effects: Ns, no side-effect information group (51.2%) < control
group (71.7%) p > 0.05
OR = 0.41 (0.17, 1.00)
Myers and Calvert
(37)
Occurrence: ? Side-effects at 3 weeks: Ns, no side-effect information group
(67.7%), beneficial information group (48.4%), control group
(73.7%), p > 0.05
–
Side-effects at 6 weeks: Ns, %), no side-effect information group
(63.6%), beneficial information group (29.6), control group (57.1%),
p > 0.05
–
Side-effects at 3 weeks: Beneficial information group (48.4%) <
combined no side-effect information group and control group
(70.5%), p < 0.05
OR = 0.39 (0.16, 0.96)
Side-effects at 6 weeks: Beneficial information group (29.6%) <
combined no side-effect information group and control group
(60.0%), p < 0.05
OR = 0.28 (0.10, 0.76)
Silvestri et al. (45) Occurrence: Chi square Erectile dysfunction: Blind to drug group (3.1%) < drug information
group (15.6%) < control group (31.2%), p < 0.01
–
Wise et al. (48) Occurrence: Logistic
regression
Headaches: No side-effect information group (29%) < control group
(37%), p = 0.02.
–
Lethargy, gastrointestinal distress, fever, rhinitis, cough, “flu,” and
skin rash: Ns
–
Ns, non-significant; M, mean, SD, standard deviation; OR, odds ratio; d, Cohen’s d; ηp2, partial eta squared; –, insufficient detail to calculate effect size; ?, not reported.
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TABLE 6 | De-emphasizing side-effects intervention results.
References Side-effect outcome and
analysis
Results Effect size (95% CI) Evidence quality
Lauder et al. (33) Occurrence: Chi square Vomiting: Ns, positive suggestion group (40.4%) < control group
(46.9%), p = 0.363
OR = 0.77 (0.43, 1.36)
+ Very Low
Nausea: Ns, positive suggestion group (63.4%) < control group
(73.2%), p = 0.148
OR = 0.64 (0.34, 1.18)
Severity: Mann Whitney U Nausea: Ns, positive suggestion group (M = 1.45, SD = 1.88) <
control group (M = 1.80, SD = 1.89), p = 0.087
d = −0.19 (−0.50, 0.13)
O’Connor et al. (38) Occurrence: Chi square Sore arm, weakness, fever: Ns –
Myalgia: Positive frame group < control group, p = 0.01 –
Chills: Positive frame group < control group, p = 0.003 –
Roscoe et al. (41) Severity: Two-way ANCOVA
with group and baseline
expectancy as two
independent factors
Average nausea: Ns, positive suggestion group (M = 1.94, SD =
1.07) < control group (M = 1.96, SD = 0.99), p > 0.05
d = −0.02 (−0.56, 0.52)
Peak nausea: Ns, positive suggestion group (M = 3.56, SD = 2.09)
< control group (M = 3.57, SD = 1.88), p > 0.05
d = −0.01 (−0.54, 0.53)
Shelke et al. (44) Occurrence: Chi square Nausea: Ns, positive suggestion group (79%) > control group
(73%), p = 0.19
OR = 1.41 (0.84, 2.37)
Severity: Independent t test Nausea: Ns, positive suggestion group (M = 1.86, SE = 0.76) >
control group (M = 1.76, SE = 0.76), p = 0.34
d = 0.01 (−0.21, 0.23)
Wilhelm et al. (47) Frequency: Independent t
test
Specific side-effects: Ns, positive suggestion group (M = 1.38, SD
= 1.56) < control group (M = 1.75, SD = 1.77), p = 0.318
d = −0.22 (−0.66, 0.22)
Nonspecific side-effects: Ns, positive suggestion group (M = 0.68,
SD = 1.02) < control group (M = 1.15, SD = 1.93), p = 0.174
d = −0.30 (−0.75, 0.14)
Severity: Independent t test Specific side-effects: Ns, positive suggestion group (M = 1.60, SD
= 2.00) < control group (M = 1.85, SD = 2.02), p = 0.580
d = −0.12 (−0.56, 0.31)
Nonspecific side-effects: Ns, positive suggestion group (M = 0.83,
SD = 1.60) < control group (M = 1.30, SD = 3.12), p = 0.396
d = −0.20 (−0.63, 0.25)
Ns, non-significant; M, mean; SE, standard error; SD, standard deviation; OR, odds ratio; d, Cohen’s d; –, insufficient detail to calculate effect size.
TABLE 7 | Miscellaneous results.
References Side-effect outcome and
analysis
Results Effect size (95% CI) Evidence quality
Rickels et al. (40) Occurrence: ? Side-effects: Ns – + Very Low
Faria et al. (29) Frequency: Independent t
test
All side-effects: Ns, p = 0.17 – +++Moderate
Drug related side-effects: Ns, covert group (M = 2.22, SD = 1.38) <
control group (M = 3.39, SD = 2.62), p = 0.06
d = −0.55 (−1.14, 0.04)
Ns, non-significant; M, mean; SD, standard deviation; d, Cohen’s d; –, insufficient detail to calculate effect size; ?, not reported.
Priming patients by informing them about the side-effects
to chemotherapy and then asking them to recall side-effects, or
by asking about their expectations of chemotherapy side-effects
overall showed little impact on side-effect reporting. This may
be due to the treatment under investigation. Chemotherapy is a
high-profile treatment, and as such it is likely patients are already
aware of the side-effects that accompany it, limiting the effect that
priming could have. In experimental studies, priming patients
using pain-related fear has been shown to increase sensitivity
to heat stimuli (55). It may be that priming patients about
side-effects to lower profile drugs find more promising effects.
Distraction techniques have been shown to be effective
in the field of pain research for example experimental and
needle-related pain (56, 57), but in terms of medication side-
effects, the evidence base is not as large, limiting conclusions.
From the results, it seems that distraction tasks should be relevant
to the patients to have the greatest chance of being effective. For
example, while video games are suitable for reducing side-effects
to chemotherapy in pediatric patients they are less effective in
adults (39, 46).
The effect of branding on side-effects shows some effect,
something also reflected in the inert literature (58). However
given the early evidence base, future studies are needed
to test the effects of branding on prescribed drugs, and
interventions to alter patients’ perceptions of prescribed generic
drugs.
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Quality of Original Research
It is possible that some of our conclusions may be due to
differences in quality between those studies that found an effect
and those that did not. We did not observe any clear trend for
lower quality studies to report more or fewer significant results
than higher quality studies. However, overall the quality of the
studies included in this review was limited due to poor reporting
of key issues in experimental research, such as randomization,
allocation concealment, blinding, and not registering a study
protocol prior to initiating recruitment. In addition, the quality
of evidence from these studies was low, partially due to these risk
of bias issues, but also the fact that the samples sizes of studies
were relatively small, adding to evidence of imprecision and
indirectness due to the wide confidence intervals, and sometimes
contradictory findings.
Quality of This Review
Search strategies for systematic reviews based on nocebo effects
are difficult to balance in terms of their specificity and sensitivity
(10). In this instance we deliberately opted for a broad search
strategy in order to identify as many relevant studies as possible.
Due to time constraints, screening, data extraction and quality
assessment were done by primarily one author. However, there
were regular weekly meetings with both authors to discuss
screening, data extraction, quality assessment and writing up of
the results, allowing us to resolve any issues as they arose.
Other limitations of the review reflect the way we grouped the
results. We aggregated studies based on the type of intervention
under investigation. These groupings contained different side-
effect outcomes, treatments and participants. It is possible that
interactions exist between these variables and the interventions
under investigation. Unfortunately, due to the small number of
studies investigating each intervention, we did not have enough
data to explore this in any depth. However, it does appear that
chemotherapy might not be as susceptible to brief psychological
interventions compared to prescription and over-the-counter
drugs.
Implications and Future Directions
Not mentioning potential side-effects to patients has the most
consistent effect in reducing side-effects to medical treatments,
especially for over-the-counter and prescription drugs. Whether
this meets ethical or regulatory requirements is debatable,
however (53, 59). De-emphasizing side-effects through positive
framing has potential and could be introduced within doctor-
patient consultations and in accompanying patient information
leaflets for patients to read at home. Further testing of this
method especially in terms of reframing side-effects as signs that
the drug is working is needed in an adequately powered trial.
In addition, it is important for future studies testing ways of de-
emphasizing side-effects to adequately compare them to a control
group that receives the standard side-effect information.
Besides framing, it is also important for doctors to
consider patients beliefs about generic medicines if prescribing
generic drugs or switching patients from a previously branded
medication to a generic. Colgan et al. (27) suggest that a simple
explanation of how the pharmacological ingredients in generic
drugs do not actually differ with branded drugs would be useful.
So far, the effects of branding have been studied in over the
counter and inert tablets: research with prescribed medication is
now needed. In addition, distraction could be beneficial for use if
age appropriate tasks are used.
Finally, only one study investigated the effect of doctor
characteristics on side-effects. This represents a surprising gap
in the literature. Doctor characteristics, such as empathy have
been shown to be important in benefitting patients for a range
of clinical conditions, especially pain (60). We believe this is an
important avenue for future research to investigate in terms of
benefitting patients by reducing medication side-effects.
CONCLUSION
This review was restricted by the quality and heterogeneity
of the included studies, limiting the conclusions that can be
drawn. It does however, provide an indication of which brief
psychological interventions are effective in reducing side-effects
to active medical treatment. The clearest effect was from omitting
information about side-effects to participants before exposure.
Although withholding side-effect information would be one way
to reduce this, it is ethically and legally problematic. Current
work is looking at how we can effectively de-emphasize side-
effects while still giving patients the information needed for
informed consent, and this shows promise. Potential strategies
include positively framing the risk of side-effects, focusing more
on the benefits of the drug, and framing side-effects in terms
of signs that the drug is working. However further research is
needed in larger trials with suitable control groups. There is also
a gap for future research to consider doctor characteristics, such
as empathy, as a means of reducing patients’ experience of side-
effects. Finally, better reporting of studies is essential in future,
allowing for more concrete determinations of study quality.
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